Von Eschenbach joins Greenleaf
This article was originally published in The Tan Sheet
Executive Summary
Former FDA Commissioner Andrew von Eschenbach teams with his former chief of staff, Patrick Ronan, as a senior advisor at Greenleaf Health - a regulatory consulting firm Ronan founded in 2006 with offices in New York and Washington. Von Eschenbach says Greenleaf is a great "launching pad" to contribute to macro health care issues, such as personalized medicine, genomics and informatics. He cannot advocate directly to FDA on behalf of a third party for the next year and he has a lifetime ban on lobbying FDA on rules he influenced as commissioner. Eschenbach also says a return is in the works to the University of Texas M.D. Anderson Cancer Center in Houston, where he spent 25 years in various leadership positions before being named director of the National Cancer Institute in 2000. At M.D. Anderson he will be an adjunct professor and will serve on the advisory board of the David Koch Center for Applied Research in Genitourinary Cancers
You may also be interested in...
People In Brief
HPM partner McNamara dies: Stephen H. McNamara, a partner in the Hyman, Phelps & McNamara law firm and a congressional advisor on the Dietary Supplement Health and Education Act, died Dec. 28 of complications from cancer at the age of 66. McNamara's wife Caroline, children Matthew and Deborah and six grandchildren survive him. He was a member of HPM from 1984 until poor health forced his withdrawal from practice in 2003. He advised Congress in the development of DSHEA, which passed in 1994. Prior to joining HPM, McNamara was senior vice president and general counsel for the Cosmetic, Toiletry and Fragrance Association (now the Personal Care Products Council). He also was a staff attorney at FDA, a senior trial attorney and the associate chief counsel for food. He served as acting chief counsel for about a year and was twice given the FDA Award of Merit, the agency's highest service award. McNamara served as a chaplain's assistant in the U.S. Army from 1967-1969, and was awarded the Bronze Star, the Purple Heart and the Army Commendation Medal
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.